证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-049 江苏鱼跃医疗设备股份有限公司 关于开展外汇套期保值业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、公司及控股子公司拟开展的产品主要为外汇套期保值产品，自公司第六届董事 会第十五次临时会议审议通过之日起12个月内任一时点的交易金额（含前述投资的收益 进行再投资的相关金额）不超过3亿美元或等值人民币，相关业务保证金上限为2000万 美元或等值人民币。本次投资以规避和防范汇率风险为目的，资金使用安排合理，不会 影响公司主营业务的发展。交易场所为经有关政府部门批准、具有外汇套期保值业务经 营资质的金融机构。 2、审议程序：本次关于《公司开展外汇套期保值业务》的议案已经公司第六届董 事会审计委员会2025年第六次会议、第六届董事会第十五次临时会议审议通过。本事项 在董事会审批权限内，无需提交股东会审议。 3、风险提示：公司及控股子公司拟开展与日常经营相关的外汇套期保值业务主要 是为了降低市场波动对公司经营及损益带来的影响，但也可能存在市场风险、流动性风 险、信用风险、 ...

江苏鱼跃医疗设备股份有限公司 关于开展外汇套期保值业务的可行性分析报告 一、开展外汇套期保值业务概述 （一）开展外汇套期保值业务的目的 鉴于近期国际经济、金融环境波动频繁等多重因素的影响，人民币汇率波动的不确 定性增强，为防范汇率及利率波动风险，降低市场波动对江苏鱼跃医疗设备股份有限公 司（以下简称"公司"）经营及损益带来的影响，公司拟开展与日常经营相关的外汇套 期保值业务。 公司及控股子公司开展外汇套期保值业务投入的资金来源为自有资金、债务融资以 及公司通过法律法规允许的其他方式筹集的资金，不涉及募集资金。 5、外汇套期保值业务授权 本次投资不会影响公司主营业务的发展，公司资金使用安排合理。根据相关会计准 则，本次投资符合套期保值相关规定。 （二）开展外汇套期保值业务的情况 1、外汇套期保值涉及币种及业务品种 公司及控股子公司拟开展的外汇套期保值业务只限于从事与公司生产经营所使用 的主要结算货币相同的币种（主要外币币种有美元、欧元等），在境内外商业银行办理 的以规避和锁定汇率及利率风险和成本为目的的交易，包括远期结售汇、外汇掉期、外 汇期权等外汇衍生产品业务。结合日常业务需要，公司及控股子公司拟开展的产品主 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-048 江苏鱼跃医疗设备股份有限公司 第六届董事会第十五次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 12 月 24 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"）以通讯 表决的方式召开了第六届董事会第十五次临时会议。公司于 2025 年 12 月 19 日以书面 送达及电子邮件方式向公司全体董事发出了召开公司第六届董事会第十五次临时会议 的通知以及提交审议的议案。会议应出席董事 9 名，实际出席会议董事 9 名。本次会议 的召集、召开及表决等程序符合《中华人民共和国公司法》和《公司章程》的有关规定， 会议决议合法、有效。会议由董事长吴群先生主持，经与会董事充分讨论，审议通过了 如下议案： 二、董事会会议审议情况 1、 关于《公司开展外汇套期保值业务》的议案 1、第六届董事会第十五次临时会议决议； 2、第六届董事会审计委员会 2025 年第六次会议决议。 特此公告。 江苏鱼跃医疗设备股份有限公司董事会 二〇二五年十二月二十五日 董事 ...

证券日报网讯12月22日，鱼跃医疗（002223）在互动平台回答投资者提问时表示，截至2025年12月10日 公司股东总户数为50000多户。 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

Core Viewpoint - The healthcare sector experienced a broad rally, with several stocks showing significant activity, driven by the launch of Ant Group's AI health application "Antifufu" which has over 15 million monthly active users and ranked second on the Apple App Store download list [1] Group 1: Stock Performance - Meian Health surged over 10% [1] - Weining Health increased by 8.65% [1] - Industry leader Alibaba Health rose by 2.47% [1] - Yuyue Medical saw a slight increase of 0.76% [1] Group 2: Market Sentiment - The integration of AI technology with health management is expected to open new growth opportunities, positively impacting overall market sentiment in the healthcare sector [1]

Core Insights - The global life support medical device market is projected to reach $75.1 billion in 2024 and is expected to exceed $80 billion in 2025, with a potential to surpass $100 billion in the next five years [3][5] - The domestic life support medical device market in China is rapidly growing, with an estimated market size of 55.7 billion yuan in 2024, expected to reach 61.95 billion yuan in 2025, and potentially reaching 93.2 billion yuan in the next five years [5] Industry Definition and Classification - Life support medical devices are critical equipment used to replace or assist the function of vital organs in emergency situations, primarily utilized in ICUs, emergency rooms, operating rooms, and pre-hospital care [2][3] - Key categories of life support medical devices include blood purification equipment, monitors, ventilators, anesthesia machines, ECG machines, defibrillators, and CPR devices [2][3] Current Industry Development - The life support medical device sector is characterized by high-risk equipment that plays a crucial role in medical rescue and care [3] - The industry has seen rapid market expansion, with significant growth expected in the coming years [3][5] Industry Chain - The upstream of the life support medical device industry includes raw materials, electronic components, biological materials, high-performance batteries, precision sensors, packaging materials, and software systems [5] - The midstream focuses on the research and manufacturing of life support medical devices, while the downstream includes medical institutions, home users, and rehabilitation centers [5] Competitive Landscape - The life support medical device market is marked by high technical barriers and growth potential, with leading domestic companies including Mindray, Yuyue Medical, and Weigao [7] - The market is relatively concentrated, with foreign companies dominating the high-end segment while domestic brands are making breakthroughs in the mid-to-low end and advancing towards high-end products [7] Development Trends - The life support medical device industry is increasingly recognized as essential in modern medicine, with a focus on integrated, precise, and intelligent technologies [10] - The demand for life support medical devices is expected to grow due to the aging population and the rising need for critical care related to severe and emergency patients [10]

Core Insights - Taobao Flash Sale launched the "17 Cities Knight Day" event in 58 cities across China, including major cities like Beijing and Shanghai, to support new employment forms and provide services for urban riders [1][3] - The event included the establishment of a support center for urban riders in Changsha, aiming to enhance community engagement and recognition for these workers [1][3] Group 1 - The "City Knight Day" will be held monthly on the 17th starting from May 17, 2025, with over one million riders currently engaged in the program [3] - The "Blue Knight" program has been upgraded to "City Knight," featuring new uniforms equipped with safety gear and medical supplies [3] Group 2 - Yuyue Medical donated 1 million emergency care packages valued at 38 million yuan to Taobao Flash Sale riders, enhancing their safety during deliveries [5] - The emergency care packages have proven effective in real-life situations, providing immediate assistance to individuals in need [5] - Taobao Flash Sale is committed to building a comprehensive support and development system for urban riders, ensuring they receive respect and recognition for their work [5]

证券日报网讯 12月12日，鱼跃医疗（002223）在互动平台回答投资者提问时表示，目前公司暂无外骨 骼助力行走器产品。公司产品品类丰富，可为院内外场景下老年人群体提供多重健康保障与支持，例 如，公司的呼吸治疗、糖尿病护理、家用健康检测、康复及临床器械等板块，均有产品可参与到相关领 域。未来公司会在坚定围绕主营业务的同时，密切关注前沿技术与市场需求动向，并完善公司业务布 局，以持续提升公司核心竞争力与长期稳健发展。 ...

Core Viewpoint - The ban on the production of mercury thermometers and sphygmomanometers starting next year has sparked significant discussion on social media, with various medical device companies responding to the news and indicating minimal impact on their operations [1] Company Responses - Yuyue Medical stated that it will strictly comply with national laws and regulations, and the ban will not significantly affect its business as it has been focusing on developing electronic blood pressure monitors and thermometers [1] - Cofo Medical mentioned that its primary products are infrared thermometers, indicating no reliance on mercury thermometers [1] - Jiann Medical confirmed that it has never produced mercury thermometers, focusing instead on electronic models [1] - Yingqu Technology noted that its thermometer business is relatively small and primarily consists of electronic types [1] - Aojiahua stated that it does not produce mercury thermometers, highlighting its offering of infrared thermometers [1]